Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries

Marliana S. Rejeki, Nana Sarnadi, Retno Wihatusti, Vininta Fazharyasti, Wisvici Y. Samina, Frilasita A. Yudhaputri, Edison Johar, Neni Nurainy, Novilia S. Bachtiar, David H. Muljono

Gatot Soebroto Central Army Hospital (RSPAD), Jl. Abdul Rahman Saleh No. 24, Jakarta 10410, Indonesia
Eijkman Institute for Molecular Biology, Jl. Diponegoro 65, Jakarta 10430, Indonesia
PT Bio Farma, Jl. Pasteur No. 28, Bandung 40161, Indonesia
Faculty of Medicine, Universitas Hasanuddin, Jl. Perintis Kemerdekaan Km10, Makassar 90245, Indonesia
Faculty of Medicine and Health, University of Sydney, New South Wales, Australia

ABSTRACT

Background: We explored the outcome of convalescent plasma (CP) treatment in patients with moderate and severe coronavirus disease 2019 (COVID-19) and investigated variables for the design of further trials in Indonesia.

Methods: Hospitalised patients with moderate (n = 5) and severe (n = 5) COVID-19 were recruited and transfused with CP from donors who recovered from mild (n = 5), moderate (n = 5), or severe (n = 1) COVID-19. Neutralising antibodies (NAbs) to the virus were measured at the end of the study using a surrogate virus neutralisation test as an alternative to the plaque reduction assay. Clinical improvement was assessed based on the modified World Health Organization Research and Development Blueprint six-point scale, Brixia Chest-X-Ray scoring, and laboratory parameters. The study was registered at ClinicalTrials.gov (NCT04407208).

Findings: CP transfusion in three doses of 3 mL/kg of recipient body weight at 2-day intervals was well tolerated. Good clinical improvement was achieved in all patients with moderate disease and in two patients with severe disease. Most patients at baseline had detectable NAbs with median inhibition rates comparable to those of the donors (90.91% vs. 86.31%; p = 0.379). This could be due to the unavailability of pre-donation NAb testing and postponed CP administration that required communal consent.

Interpretation: This study highlights the safety of CP therapy. Although improvements were observed, we could not conclude that the outcomes were solely due to CP treatment. Further randomised controlled trials that cover different disease stages with pre-donation NAb measurements using locally applicable strategies are warranted.

Funding: The study was supported by PT Bio Farma, Indonesia.

Keywords: COVID-19, coronavirus, SARS-CoV-2, convalescent plasma, moderate, severe, LMIC, low- and middle-income countries, Indonesia

1. Introduction

Following the first cases identified in Wuhan, China, in December 2019, the epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has rapidly spread worldwide [1]. The disease, named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), was declared a global pandemic on March 11, 2020 [2]. While China and high-income countries (HICs) in the northern part of Europe and North America experienced major outbreaks in the first quarter of 2020, low- and middle-income countries (LMICs) in Latin America and the southern part of Asia began to see spikes in cases in early April 2020 [3,4].

 Currently, no effective treatments are approved for COVID-19 [5]. Convalescent plasma (CP), a form of passive antibody immunotherapy, has been used to treat 1918 influenza, severe acute respiratory syndrome, pandemic 2009 influenza A (H1N1), avian influenza A (H5N1), Ebola, and other viral infections, and was associated with reduced mortality [6,7]. Initial case series of critically ill patients with COVID-19 treated with CP did not show serious adverse events amongst the participants, with some showing good improvements. However, most studies lacked adjustments for critical confounders.

https://doi.org/10.1016/j.eclinm.2021.100931
2589-5370/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Research in context

Evidence before this study

Convalescent plasma (CP) has been the subject of increasing expectation for treating coronavirus disease 2019 (COVID-19). Reports on CP transfusion have shown promising clinical improvements without serious adverse events. Most studies focused on reporting CP treatment in patients with severe COVID-19, but only a few addressed benefits on less severe disease. The vast majority of studies reporting COVID-19 infection and treatment have come from earlier affected countries with established health systems and research infrastructure, while very few are from low- and middle-income countries (LMICs). Nonetheless, CP therapy could be one of the few available options in LMICs where constraints may exist in the access to novel treatments, even once available. Clinical trials conducted in LMICs may differ in many respects from those in high-income countries.

Added value of this study

This study indicated the safety and potential benefit of CP therapy for patients with COVID-19. Measurement of NAb titres against SARS-CoV-2 in CP units before transfusion is key to ensure adequate antibody levels. As an alternative of the plaque reduction assay, a surrogate virus neutralization test was used to detect and quantify NAb titres. Lower NAb inhibition rates were found in CP donors who previously had mild COVID-19 compared to those with moderate or severe disease. Most CP-receiving patients had high NAb titres before CP transfusion. This could be due to the late timing of CP treatment that was given after endogenous antibodies had been synthesized. Simple tools such as the chest X-ray scoring system are helpful for assessing and monitoring lung involvement in COVID-19. In LMICs, community leaders need to be involved to educate how people view risks and benefits of research, thus affecting decision making to participate in the trial.

Implications of all the available evidence

The use of surrogate methods as alternatives for conventional neutralization tests is important in selecting potential donors in LMICs. Recruitment of recovered patients who had more severe disease and storage of plasma samples at −20°C for later NAb testing would be a solution for quick deployment of CP. Late administration of CP in the course of disease did not provide better benefits to the patients. Further well-designed randomized trials of CP treatment that cover the full spectrum of illness, from mild disease to complete recovery or death, are warranted. This study underscores the importance of community engagement and taking seriously the characteristics of local structures and values in LMICs to obtain supports for the trials.

including co-treatments, baseline characteristics, disease severity, and timing of administration.

Since these initial studies, multiple trials have been initiated and reported. However, data from several larger studies, albeit supporting the safety of CP, did not show the overall efficacy of this treatment. A randomised control trial from China, which only included patients with severe or life-threatening COVID-19, was terminated early and was considered underpowered to define significant differences between the treatment and control groups [8]. Two studies from the Netherlands and Spain were also terminated prematurely—the Dutch study because interim analysis concluded the need for redesign of the trial [9] and the Spanish study because of inadequate patient enrolment [10]. In the Dutch study, most of the patients already had high neutralising antibody (NAb) titres at the time of inclusion, and no statistical differences in outcomes were observed between the treated and untreated groups [9,10].

Further studies have been published and assessed in several systematic reviews that remain uncertain about the safety and effectiveness of CP treatment for COVID-19 [11-14]. Some studies, which were not conducted in a prospective manner, were non-randomised, or lacked untreated control arms, support the concept that CP should be administered before the disease is life-threatening to clear the virus more rapidly and to avoid further tissue damage [11,15]. Meanwhile, CP treatment has been increasingly adopted in clinical practice despite the regulatory approval in some countries that limit its use under an Emergency Use Authorization (EUA) law or in the context of clinical trials. The distribution of CP trials is centred in the countries most affected by COVID-19—predominantly in HICs [16], where large-scale procurement and stockpiling of CP has been undertaken. [17] In contrast, less than one-third of the trials are conducted in LMICs, with challenges pertaining to the provision of CP and limited capacity for pre-donation qualification [16,18].

Indonesia confirmed its first case on March 2, 2020. As of April 9, 2020, the pandemic had spread to 34 provinces in the country and continued to increase, eventually holding the highest number of cases in Southeast Asia on June 17, 2020 [19]. Due to the lack of treatment options for COVID-19, CP therapy was seen as a potential therapeutic strategy. As an LMIC with a geographically dispersed archipelago, access to healthcare remains a challenge in remote districts that could impact the adoption of CP deployment in Indonesia [17,20]. With the diverse social, cultural, and structural values of Indonesia, a well-designed trial protocol needs to be developed to ensure that the intervention and implementation are suitable in the local context [21]. We conducted this preliminary study to explore the effectiveness and safety of CP treatment in patients with moderate and severe COVID-19 and to investigate variables relevant for the design of future trials in Indonesia [22].

2. Methods

2.1. Study design and participants

The study was conducted at Gatot Soebroto Central Army Hospital (RSPAD) in collaboration with the Eijkman Institute for Molecular Biology and PT Bio Farma from May 1, 2020 to July 31, 2020. Ten hospitalised patients (male/female: 5/5) with COVID-19 with a median age of 56.6 (range: 42–75) years were enrolled (Table 1). All the patients were diagnosed with COVID-19 using SARS-CoV-2 quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swab samples at admission. Written informed consent was obtained from each patient or their legal relatives. The study was approved by the Health Research Ethics Committee, Bethesda Hospital, Yogyakarta (No.77/KEPK-RSB/JV/2020) and registered at ClinicalTrials.gov (NCT04407208).

2.2. Procurement and administration of CP

Voluntary CP donors were recruited based on the following criteria: aged 18–60 years, previously diagnosed with COVID-19 by RT-PCR, discharged from hospital, and symptom-free for more than 14 days. All donors gave written consent for plasma donation through the plasmapheresis procedure and met the standard criteria for blood donation, including seronegativity for hepatitis B, hepatitis C, human immunodeficiency virus, and syphilis [21]. From each donor, 500–600 mL plasma was collected by the apheresis procedure using an MCS+ 9000 (Haemonetics, USA), which was aliquoted into four 100–150 mL plasma units and immediately stored at −20 °C.

SARS-CoV-2 NAbs in plasma were not measured before transfusion, as quantification assays were not available at the beginning of
the study. An aliquot of plasma was kept at −20 °C for later investigation. CP transfusion was administered in three doses at 2-day intervals (approximately 3 mL/kg of recipient body weight) [23]. The transfusion was administered at 10–20 mL for the first 15 min, which was slowly increased and completed in 4 h. The recipient was closely monitored for 6 h after transfusion. The CP units were mostly from the same donors, although they could have been from different donors according to availability.

2.3. Definition of disease severity and assessment of outcomes

Clinical symptoms were recorded daily. Routine haematological tests were performed every 2–3 days, while biochemical, immunological, and lung imaging and SARS-CoV-2 RT-PCR was repeated every week. COVID-19 severity was defined according to the classification proposed by Siddiqi and Mehra and the WHO Interim Guidance (May 27, 2020) on Clinical Management of COVID-19 [24,25]. Mild grade (Stage I) was defined as disease with few symptoms (low fever, fatigue) and without pulmonary imaging (radiography or computed tomography [CT]) findings. Moderate grade (Stage II) was defined as disease with fever, respiratory symptoms (dry cough, chest distress, or shortness of breath after activities), and pulmonary imaging findings, subdivided into Stage IIa (without hypoxia) and Stage IIb (with hypoxia). Severe grade (Stage III) was defined as disease with a respiratory rate 

| Patient No | Sex | Age (year) | Clinical stage* | Days from symptom onset to hospital admission | Days from symptom onset to CP* therapy | Days from hospital admission to CP* therapy | Principal Symptoms | Comorbidity |
|------------|-----|------------|----------------|---------------------------------------------|---------------------------------------|-------------------------------------------|-------------------|-------------|
| 1*         | F   | 48         | Severe         | 14                                          | 17                                    | 3                                         | Fever, cough, shortness of breath, nausea | None          |
| 2*         | M   | 51         | Moderate       | 9                                           | 17                                    | 8                                         | Fever, cough, shortness of breath         | None          |
| 3*         | M   | 58         | Severe         | 5                                           | 17                                    | 12                                        | Fever, cough, shortness of breath         | Hypertension   |
| 4          | M   | 52         | Moderate       | 4                                           | 14                                    | 14                                        | Cough                                        | Diabetes mellitus|
| 5          | F   | 54         | Moderate       | 6                                           | 14                                    | 8                                         | Fever, cough                                | None          |
| 6          | M   | 72         | Moderate       | 4                                           | 14                                    | 10                                        | Fever, cough                                | Diabetes mellitus|
| 7          | F   | 54         | Moderate       | 6                                           | 28                                    | 22                                        | Fever, diarrhoea                            | None          |
| 8          | M   | 42         | Severe         | 6                                           | 14                                    | 8                                         | Anosmia, ILI†                                | None          |
| 9          | F   | 60         | Severe         | 2                                           | 6                                      | 4                                         | Fever, shortness of breath, ILI†           | Diabetes mellitus|
| 10         | F   | 75         | Severe         | 2                                           | 28                                    | 26                                        | Shortness of breath, fever                 | None          |

*According to Siddiqi and Mehra.[24]*

†ILI, influenza-like illness.

2.4. Detection of SARS-CoV-2 and measurement of NAbs

Nucleic acid was extracted from nasopharyngeal swabs in viral transport medium using a QIAamp Viral RNA Mini Kit (QIAGEN, Germany), and RT-PCR was performed using A*Star Fortitude Kit 2.0 (DxD Hub, Singapore) on a CFX96TM Real-Time PCR Detection System (Bio-Rad, USA), in accordance with the manufacturer’s instructions. A cycle threshold (CT) value of <40.0 was considered positive.

NAb against the receptor binding domain (RBD) of SARS-COV-2 spike protein was measured using the cPass™ surrogate virus neutralisation test (sVNT) (GenScript, USA) at the end of the study [28]. The assay was a competitive enzyme-linked immunosorbent assay between the RBD with human angiotensin converting enzyme-2 [28] which was amongst the first tests to obtain an EUA from the US Food and Drug Administration [29]. It was performed according to the manufacturer’s instructions with slight modifications [30]. Briefly, samples were heat-inactivated at 56 °C for 30 min before the test, and incubated with an equal volume of horseradish peroxidase-conjugated RBD (HRP-RBD) at 37 °C for 30 min. The serum/HRP-RBD mix (100 μL) was then added to each well and incubated at 37 °C for 15 min. After removing unbound HRP-RBD by four washes, a chromogenic substrate provided in the kit was added, followed by incubation at 25 °C for 15 min. The colorimetric reaction was terminated by the addition of a stop solution. Absorbance was measured at 450 nm. The reciprocal of the maximal dilution with 50% inhibition was counted as the NAb titre in the tested serum samples. An inhibition rate of >20% was considered positive for NAbs.

2.5. Radiological examination

Brixiia Chest X-ray (CXR) scoring system according to Borghesi and Maroldi was used to monitor the progression of lung involvement [31]. This CXR scoring system includes two steps of image analysis. In the first step, each lung was divided into three zones on the frontal projection, marked by letters A, B, and C for the right lung, and D, E, and F for the left lung. The letters divide the lungs into three levels: upper level (A and D), above the inferior wall of the aortic arch; middle level (B and E), below the inferior wall of the aortic arch and above the inferior wall of the right inferior pulmonary vein (the hilar structures); and lower level (C and F), below the inferior wall of the right inferior pulmonary vein (the lung bases). A score (from 0 to 3) was assigned to each zone based on the detected lung abnormalities: 0, no lung abnormalities; 1, interstitial infiltrates; 2, interstitial and alveolar infiltrates (interstitial pre-dominance); and 3, interstitial and alveolar infiltrates (alveolar predominance). The overall CXR score is the sum of points from the six lung zones with a range from 0 to 18, followed by the partial score of each zone presented between square brackets.

2.6. Statistical analyses

Continuous variables were presented as medians and ranges. Categorical variables were expressed as counts and percentages and compared using the Chi-square or Fisher’s exact test as appropriate. Tests were two-sided, and P values <0.05 were considered statistically significant. Statistical analyses were performed using the Statistical Program...
for Social Sciences (IBM SPSS version 22.0 for Windows; SPSS, IL, USA). Graphs were plotted using GraphPad Prism version 7•0.

2.7. Role of the funding source

The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

2.8. STROBE guidelines

The present study adheres to the STROBE reporting guidelines.

3. Results

3.1. Characteristics of patients and donors

The most common symptoms of patients at presentation were fever, non-productive cough, shortness of breath, anosmia, and diarrhoea. The patients were classified as moderate (n = 5) or severe (n = 5) COVID-19 [24,25], with five patients having comorbidities, including hypertension (n = 1) and diabetes mellitus (n = 4). The median time from onset of symptoms to hospital admission was 6 (range: 2–17) days, while the median time from symptom onset and hospital admission to CP transfusion was 16 (range: 6–28) days and 9 (range: 3–26) days, respectively (Table 1). Both groups of patients also received oral antivirals (oseltamivir and/or favipiravir and/or ritonavir/lopinavir) and supportive treatments according to the Indonesian National Guidelines [32]. Antibacterial therapy was administered to patients with suspected coinfection [25,32]. Corticosteroids (methylprednisolone or dexamethasone) were administered to severe patients under mechanical ventilation [33].

Eleven convalescent patients (male/female: 7/4) with a median age of 35 (range: 23–56) years who recovered from various stages (mild [n = 5], moderate [n = 5], and severe [n = 1]) of COVID-19 were enrolled as donors (Table 2). None of the female donors were ever pregnant. The median time from symptom onset and hospital discharge to plasma collection was 22 (range: 23–56) days and 14 (range: 14–20) days, respectively.

3.2. CP treatment, clinical response, respiratory function, and chest radiography findings

Symptoms in all patients, especially fever, cough, and chest pain, were largely alleviated within 1 to 3 days following the first unit of CP transfusion. Before CP treatment, four patients required mechanical ventilation and six required conventional nasal cannula oxygenation. In the first 2 weeks, four patients were still on mechanical ventilation; two of the four patients (Patients 3 and 9) who had comorbidities continued to deteriorate and passed at week 3.

There were clinical improvements as measured by the modified WHO six-point ordinal scale at 28 days of follow-up [27]; four patients were discharged from the hospital, two were treated without supplemental oxygenation, and one was treated with nasal oxygenation (Table 3). One patient (Patient 10) still required mechanical ventilation despite having improved clinical and laboratory parameters in the previous weeks. This patient had a positive bronchial lavage culture for Klebsiella pneumoniae.

The overall median PaO2/FiO2 ratio was 276 (range: 101–466) mmHg before CP transfusion and fluctuated at weeks 1 and 2. At weeks 3 and 4, the PaO2/FiO2 ratio improved in eight patients, but remained low (<300) in the deceased patients. Chest radiography findings showed improvements in overall CXR scores in surviving patients, from a median of 14 (range: 7–16) at baseline to a median of 14 (range: 7–16), 11 (range: 4–14), 9 (range: 2–12), and 7 (range: 2–7) at weeks 1, 2, 3, and 4, respectively (Fig. 1a and Suppl. Table 3).

3.3. Laboratory findings

The neutrophil-to-lymphocyte ratio (NLR), a predictor of prognosis in COVID-19 [34], fluctuated between weeks 1 and 3 after CP treatment, but decreased at week 4 in surviving patients. C-reactive protein (CRP), an index for disease progression, significantly improved in most patients compared with baseline levels. A decrement tendency of other inflammatory parameters, interleukin (IL)–6 and procalcitonin, was documented in most surviving patients after CP therapy compared with the baseline levels (Fig. 2).

A decline in d-dimer, a marker for inflammation and prothrombotic state, was also observed in most patients following CP transfusion, except for an obvious increase in Patient 1. However, other coagulation markers, including platelet count and prothrombin time, did not show significant changes in the majority of the patients (Fig. 2). Similarly, parameters indicative of organ dysfunction, including alanine aminotransferase, bilirubin, and creatinine, remained unchanged compared with their pre-treatment levels (Table 2), except for Patient 9, who experienced kidney failure. By clinical stage, better reduction tendencies of these markers were observed amongst patients with moderate disease compared with those with severe disease (Suppl. Fig. 1).

Measurement of the degree of organ dysfunction showed a decrease in the SOFA scores in most patients who survived by the end of the trial (Fig. 1B), except for Patients 3 and 9, who had SOFA scores of 5 and 11, respectively.

3.4. Changes in viral load and SARS-CoV-2 NAb

All patients had detectable viral nucleic acid levels upon admission. Before CP transfusion, the median Ct value was 33.2 (range: 21.5–43.1). It progressed to 35.5 (range: 15.4–43.3), 35.1 (range:
already negative at baseline. On the other hand, three patients of the trial, including the two patients (Patients 1 and 10) who were respectively. Five patients were negative for SARS-CoV-2 at the end weeks 1, 2, 3, and 4 after the CP transfusion (Table 2 and Fig. 3),

Table 3
Comparison of clinical characteristics and laboratory parameters of patients receiving convalescent plasma transfusion.

| Parameter                  | Baseline (n = 10) | Week 1 (n = 10) | Week 2 (n = 10) | Week 3 (n = 8) | Week 4 (n = 8) |
|---------------------------|-------------------|----------------|----------------|---------------|---------------|
| Haemoglobin (g/dL)        | 12.4 (9.7–15)     | 12.2 (8.3–14.5)| 11.5 (9.1–14.9)| 11.6 (10.5–15.0)| 11.4 (8.6–15.9) |
| Leucocyte (x10⁶/mL)       | 9.7 (4.1–23.8)    | 9.0 (5.2–32.4) | 11.6 (7.7–53.5) | 11.9 (9.0–22.3) | 10.4 (5.4–12.5) |
| Neutrophil (x10⁶/mL)      | 81 (41–96)        | 88 (65–96)     | 91 (66–97)     | 87 (62–95)     | 72 (65–96)     |
| Lymphocyte (x10⁶/mL)      | 13 (2–44)         | 5 (2–28)       | 5 (1–27)       | 7 (3–30)       | 16 (2–21)     |
| NLR ≥ 3                   | 8 (80%)           | 6 (60%)        | 7 (70%)        | 6 (73%)        | 1 (12.5%)    |
| Thrombocyte (x10⁹/mL)     | 268 (112–384)     | 293 (53–777)   | 322 (108–721)  | 358 (141–772)  | 281 (123–332) |
| Prothrombin time (second) | 10 (9.7–12.0)     | 11 (9.7–12.3)  | 10 (9.6–11.4)  | 10 (9.7–10.8)  | 10 (9.9–13.8) |
| INR ≥ 6                   | 3 (30%)           | 4 (40%)        | 3 (30%)        | 2 (23%)        | 4 (50%)      |
| D-Dimer (µg/mL) ≥ 0.5     | 6 (60%)           | 3 (30%)        | 6 (60%)        | 3 (37.5%)      | 0 (62.5%)    |
| Procalcitonin (ng/mL) ≥ 0.5 | 0.25 (0.03–5.61) | 0.20 (0.02–7.27) | 0.09 (0.05–10.16) | 0.06 (0.03–0.11) | 0.10 (0.02–0.04) |
| Interleukin-6 (µg/mL) ≥ 5 | 1 (10%)           | 3 (30%)        | 2 (20%)        | 1 (12.5%)      | 2 (25%)      |
| Aspartate aminotransferase (IU/L) ≥ 300 | 19 (1.5–79) | 1.7 (1.5–66.6) | 5.2 (1.5–125.6) | 1.5 (1.5–13.6) | 0 (1.5–82.9) |
| Alanine aminotransferase (IU/L) ≥ 300 | 25.5 (22–126) | 24 (11–69)     | 29 (13–107)    | 38 (14–229)    | 22 (13–74)   |
| Total Bilirubin (mg/dL) ≥ 6 | 0.6 (0.3–1.5)    | 0.4 (0.2–1.7)  | 0.5 (0.2–1.8)  | 0.6 (0.2–1.2)  | 0.5 (0.4–1.1) |
| Creatinine ≥ 8 mg/dL      | 0.8 (0.6–1.4)     | 0.8 (0.6–3.5)  | 0.9 (0.5–4.9)  | 0.7 (0.5–1.1)  | 0.7 (0.65–1.6) |
| Six-category scale:       |                   |               |               |               |               |
| Discharged                | 4 (40%)           |               |               |               |               |
| Hospitalization, no supplemental oxygen | 4 (50%) |               |               |               |               |
| Hospitalization, requiring low-flow supplemental oxygen | 6 (60%) | 5 (50%) | 5 (50%) | 5 (50%) | 1 (12.5%) |
| Hospitalization, requiring HFNC/non-invasive ventilation | 1 (10%) | 1 (10%) | 1 (10%) | 1 (10%) |               |
| Hospitalization, requiring ECMO/invasive ventilation | 4 (40%) | 4 (40%) | 4 (40%) | 2 (20%) | 1 (12.5%) |

Data are median (range) or n (%); NLR, Neutrophil-to-lymphocyte ratio; CRP, C-reactive protein; INR, International Normalized Ratio; SOFA, Sequential Organ Failure Assessment.

HFNC, high-flow nasal cannula; ECMO, Extracorporeal membrane oxygenation.

21–45.2), 37–1 (range: 23.8–43.1), and 40.2 (range: 28.8–49.8) at weeks 1, 2, 3, and 4 after the CP transfusion (Table 2 and Fig. 3), respectively. Five patients were negative for SARS-CoV-2 at the end of the trial, including the two patients (Patients 1 and 10) who were already negative at baseline. On the other hand, three patients remained positive for SARS-CoV-2 until the end of the trial.

The NAb titres against SARS-CoV-2 in donors before transfusion and in CP-receiving patients could not be determined when the study began. Utilising a recently available sVNT [28], we were able to measure the antibody inhibition activity in the donors and patients. Figs. 4A and 4B illustrate the inhibition rates of NAbS in CP units administered to individual patients and in CP-receiving patients.
across the weeks of administration. amongst the donors, eight (72.7%) had detectable NAbs with a median inhibition rate of 86-1% (range: 63-41%–94-53%), while three (22.7%) had inhibition rates lower than the cut-off value (20%). Of the patients, nine had detectable NAbs before receiving CP with a median inhibition rate of 90-9% (range: 38-66%–95-13%) (Suppl. Table 1).

Some patients had high NAb inhibition rates (>90%) even before the first CP administration: four patients (Patients 1, 2, 6, and 7) had

---

**Fig. 2.** Changes of inflammatory (A-D) and coagulation (E-F) parameters in CP-receiving patients. Horizontal axis represents the pre- (baseline) and post-transfusion weeks.

**Fig. 3.** Changes of viral load in nasopharyngeal swabs amongst CP-receiving patients. Horizontal axis represents the pre- (baseline) and post-transfusion weeks. Dashed lines indicate the detection threshold at 40. Ct, cycle threshold.
CP transfusion after day 14, and one patient (Patient 3) had CP transfusion on day 5 after symptom onset (Table 1). Four patients (Patients 4, 5, 8, and 9) showed an accelerated increase in NAb inhibition following CP transfusion, including Patient 4, who passed away at week 3 (Suppl. Table 3). Delays in CP administration were mostly due to consent-related issues, particularly in three patients (Patients 3, 7, and 10) who required agreement from the community leaders. The NAb median inhibition rates in the patients at baseline and in the donors were comparable (90-91% [range: 38.66%–95.13%] vs. 86-31% [range: 78.08%–94.53%], respectively: p = 0.379).

3.5. Adverse effects

No noticeable adverse effects were observed with CP transfusion. Deaths occurred in two patients with severe COVID-19 who initially had comorbidities and experienced refractory multi-organ dysfunction.

4. Discussion

CP has been regarded with great expectations for treating COVID-19. However, it has not been approved as a standard of care for the disease. Adequate trials are necessary to definitively demonstrate its efficacy in determining the optimal product attributes and appropriate patient populations. Most studies reported CP treatment in patients with severe COVID-19 [8,35–39], although only a few addressed the possible impact on less severe disease [30,40].

To date, the vast majority of studies reporting COVID-19 infection and treatment have come from the earlier affected countries with established healthcare systems and better research infrastructure, while critical research questions specific to the needs of LMICs are difficult to answer [17,41]. A disproportionate impact is observed in the latter with their constraints for swift uptake of new technologies and medical supplies to deal with this pandemic [18]. In these countries, challenges prevail pertaining to the availability of resources for proper management and treatment of patients, such as reagents for assessing inflammation and radiological imaging for evaluating the disease course.

There are also questions regarding the capacity for donor mobilisation and CP procurement, not least of which are the pre-donation qualification and testing of NAb against SARS-CoV-2 [16,18]. In light of these issues, we performed this study using existing facilities to evaluate the effectiveness of CP therapy in patients with moderate-to-severe COVID-19, and to identify factors relevant to the outcome measure set for the design of further trials in Indonesia [22]. To the best of our knowledge, this is a timely study from Indonesia to explore the scope where CP therapy could be one of the few available options, particularly in LMICs, where challenges may exist in the access to the benefits of scientific progress for the control and treatment of COVID-19 [18,42,43].

In this study, CP transfusion administered in three doses of 3 mL/kg of recipient body weight at 2-day intervals was well tolerated. The overall assessment showed improvement in clinical symptoms, CXR findings in patients with severe COVID-19 were not in accordance with the two previous initial studies on the improvement of clinical outcomes and reduction of viral load [35,36]. The difference could be related to two key factors: the NAb titre and treatment time point, which are discussed further below.

Although the pathogenesis of COVID-19 is yet to be understood, it has been generally recognised that the disease course is attributable to two distinctive but overlapping mechanisms: (a) damage induced by virus pathogenicity, and (b) exaggeration of the host immune system [24,45]. The first is marked by common clinical symptoms such as fever, cough, fatigue, myalgia, viremia, leucocytosis, lymphopenia, and reduced CD4+ and CD8+ T cells in the peripheral blood, while the second is by over-activation of the systemic immune system, with elevation of proinflammatory and coagulation parameters [24,46]. As a result, COVID-19 presents features of a multisystem disease with impairment of several organs [47].

Virus-specific NAb contained in CP serves as the main mechanism for accelerating the clearance of virus and preventing further entry into target cells [48]. CP treatment also provides further benefit, that is immunomodulation, by neutralisation of cytokines, complement, and autoantibodies associated with COVID-19 [48,49]. This current study showed decreased levels of NLR as well as inflammatory and...
activity. This could be due to the long intervals between the onset of illness [55]. Several studies have shown that CP treatment is more effective when administered early in the disease process [35,56-58].

We observed one patient (Patient 4) who initially had negative inhibitory activity against SARS-CoV-2 NAbs. Taken together, the failure to benefit from CP therapy, studies are needed to analyse subgroups of patients to investigate the impacts of the treatment over the course of clinical illness, including non-mortal clinical outcomes [68]. In addition, they should not only represent the outcome from individual patients, but also reflect the capacity of the healthcare systems, from low- to high-income countries, to provide maximal benefit to the population [22,27].

Several lessons could be gained from this study for the design of clinical trials and deployment of CP, particularly in LMICs with resource-limited settings [18,42]: (a) whenever feasible, testing of donor’s plasma for titres of anti-SARS-CoV-2 antibodies should be performed. This is becoming enabled as surrogate methods for conventional neutralisation tests are now available in some countries [14,30], including the tests recently approved for pre-donation qualification of COVID-19 CP 0.29. If NAb titres cannot be obtained in advance, consider storing a repository from the CP donation to determine NAb titres at a later date [28,69]; (b) take advantage of the availability of a population of convalescent donors to enable stockpiling and to create inventories of CP, which can be tested for NABs before distributing the units for transfusion [6,17,40]; (c) early administration of CP in the course of disease [14,44,58]; (d) maximise utility of existing resources, as exemplified in this study in using CXR scoring to quantify and monitor lung involvement [31], where more advanced technologies such as CT are not always available or feasible. The WHO core measure outcome sets may be helpful to facilitate data pooling across the study [22]; (e) specifically for the consent process, perform community engagement and use appropriate channels to ensure that the concerns are considered when designing and implementing the intervention study [67,70].

In conclusion, this study highlights the safety of CP therapy. Although a better improvement tendency was observed amongst patients with moderate disease, we could not conclude that the
outcomes were solely due to CP treatment. It is critically important to perform well-designed randomised clinical trials of CP therapy in LMICs that cover larger patient cohorts with different stages of COVID-19, highlighting the capacity for NAb testing and treatment delivery. Locally applicable research strategies, capacity building to execute the study, translating research into the local context, and the use of recognised communicating channels need to be implemented to be obtained for support for the trials.

Authors’ contributions

MSR, NS, and RW conceptualized the study, developed the proposal, performed sample collection, laboratory work and data management, analysis, and manuscript preparation. WYS participated in proposal development and manuscript preparation. FAY and EJ participated in laboratory work, result interpretation, and manuscript preparation. NN and NSB participated in project development, result interpretation, and manuscript preparation. DHM participated in data management, analysis, interpretation of results, overall supervision, and manuscript writing. All authors read and approved the final manuscript.

Data sharing statement

The data generated and analysed in this study are included in this article and its additional files. The original datasets used for this study are not publicly available due to the existing regulation, and only can be shared upon the approval of the directors of the participating institutions.

Funding

The study was supported by PT Bio Farma, Indonesia.

Declaration of Competing Interest

Mariliana S. Rejeki reports a grant from PT Bio Farma to conduct the study. All other authors have nothing to report.

Acknowledgments

This study was funded by a non-restricted educational grant from PT Bio Farma, Bandung, Indonesia. The authors would like to extend their gratitude to Terawan Agus Putranto, Former Minister of Health, Republic of Indonesia; and Former Director of Gatot Soebroto Central Army Hospital; Rahmat Roestam, Operation Director of PT Bio Farma; Albertus Budi Sulistyadi, Director of Gatot Soebroto Central Army Hospital; and Amin Soebandrio, Chairman of the Eijkman Institute and Molecular Biology, for invaluable supports to this study. Special thanks are given to R. Triono Soendoro, for consultation and guidance in ethics principles; all colleagues from Gatot Soebroto Hospital, in particular Agus Yunianto, Handrianto Setiajaya, Lukman Ma’ruf, Marina Lily Yana, Familia Bela Rahadiati, Ratna Andriyani, Jenie Erawati Muchti, and Dwi Noviantingtyas, for assistance to execute this study; and all nurses and many others who volunteered their efforts and time. Sincere gratitude is expressed to all patients and donors who participated in this study.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.eclinm.2021.100931.

References

[1] Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China. N Engl J Med 2019;382(8):727–33 2020.

[2] WHO. Coronavirus disease (COVID-19) Pandemic 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

[3] BBC News. Coronavirus pandemic: tracking the global outbreak. 2020. https://www.bbc.com/news/world-51235105 (accessed July 31, 2020).

[4] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020.

[5] NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Updated: Feb 23, 2021]. 2020. https://www.nhlbi.nih.gov/health-topics/coronavirus
disease-2019.

[6] Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 infection . A minimal common outcome measure set for COVID-19 clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405–14.

[7] Mair-Jenkins J, Saavedra-Campos M, Ballie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dev Ctries 2015;9(11):716–21.

[8] Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clini
cal Improvement in Patients With Severe and Life-threatening COVID-19: A Ran
domized Clinical Trial. JAMA 2020;324(5):460–70.

[9] Abioyan A, Jordan CCE, GeurtsvanKessel C, et al. Convalescent Plasma for COVID-19. A randomized clinical trial. 2020. https://www.medrxiv.org/content/10.1101/2020.07.01.2019357v1.

[10] Avendano-Solá C, Ramos-Martinez A, Muñiz-Rubio E, et al. Convalescent Plasma for COVID-19: a multicenter, randomized clinical trial. 2020. https://www.medrxiv.org/content/10.1101/2020.08.26.20214444v2.

[11] Chai KL, Valk SJ, Piechotta V, et al. Convalescent plasma or hyperimmune immu
noglobulin for people with COVID-19: a living systematic review. Cochrane Data
base Syst Rev 2020;10 CD013600.

[12] Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immu
noglobulin for people with COVID-19: a living systematic review. Cochrane Data
base Syst Rev 2020;7 CD013600.

[13] Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol 2021;93(2):1111–8.

[14] U.S. Food and Drug Administration. Recommendations for Investigational COVID-
19 Convalescent Plasma. February 11, 2021. https://www.fda.gov/vaccines
/related-diseases-investigational-new-drug-device-enforcement/cess-cher/recommendations-investigational-covid-19-convalescent-plasma.

[15] Szalko L, Farkas N, Kiss S, et al. Convalescent plasma therapy for COVID-19 patients: a protocol of a prospective meta-analysis of randomized controlled tri
als. Trials 2021;22(1):112.

[16] Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent Plasma Therapy for
COVID-19: state of the Art. Clin Microbiol Rev 2020;33(4).

[17] Bloch EM, Goel R, Montemayor C, Cohn C, Tobian AAR. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries. Transfus
Apher Sci 2020:102957.

[18] Bloch EM, Goel R, Wendel S, et al. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income coun
tries. Vox Sang 2021;116:18–35.

[19] The Jakarta Post. Indonesia becomes country with most confirmed COVID-19 cases in Southeast Asia. June 17, 2020 2020. https://www.thejakartapost.com
/news/2020/06/17/indonesia-becomes-country-with-most-confirmed-covid-19-
cases-in-southeast-asia.html.

[20] The World Bank. The World Bank in Indonesia [Updated: Oct 01, 2020]. https://www.
worldbank.org/en/country/indonesia/overview (accessed November 10 2020).

[21] Smid MW, Thiery Burnouf T, 2 BJ, et al. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low- and middle-income countries. Apr 2020 https://isbtweb.org/fileadmin/user_upload/FINAL-
Points_to_consider_in_the_preparation_of_COVID-19_convalescent_plasma_in-L-
MMC.pdf (accessed May 1 2020).

[22] WHO Working Group on the Clinical Characterisation Management of COVID-19 infection . A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20(8):e192–87.

[23] Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130(6):2757–65.

[24] Siddiqui HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020;39(5):405–7.

[25] WHO. Clinical management of COVID-19. 2020. https://www.who.int/mediacentre
/items/clinical-management-of-covid-19.

[26] Jones AE, Trzeciak S, Kline JA. The Sequential Organ Failure Assessment score for pre
dicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. Crit Care Med 2009;37(5):1648–54.

[27] WHO. WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synops
is. 2020. https://www.who.int/ippin/priority-diseases/key-action/COVID-
19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf (accessed Aug 20 2020).

[28] Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockade of ACE2–spike protein-protein interaction. Nat Biotechnol 2020;38(9):1075–87.

[29] US Food and Drug Administration. Convalescent plasma letter of authorization (Reissuance, February 4, 2021). 2021 (accessed Feb 12 2021).

[30] Chen W, Zhang J, Qin X, et al. SARS-CoV-2 neutralizing antibody levels are corre
lated with severity of COVID-19 pneumonia. Biomédicine & Pharmacotherapy 2020. doi:10.1016/j.biopha.2020.110629.

[31] Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scor
ing system for quantifying and monitoring disease progression. Radiol Med 2020;125(4):509–13.
[32] Dokter Perhimpunan, Indonesia Paras. Perhimpunan dokter spesialis kardiovasku- lar Indonesia, perhimpunan dokter spesialis penyakit dalam Indonesia, perhimp- punan dokter anestesiologi dan terapi intensif Indonesia, ikatan dokter anak Indonesia, protokol tatalaksana COVID-19. Jakarta: Edisi 2. (Protocol management of COVID-19), 2020.

[33] NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Sep 1, 2020. https://www.covid19treatmentguidelines.nih.gov/.

[34] Cheng B, Hu J, Zuo X, et al. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. Clin Microbiol Infect 2020;26 (10):1400–5.

[35] Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020;117(17):9490–6.

[36] Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020;323(16):1582–9.

[37] Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 2021;384:619–29.

[38] Xu K, Chen Y, Yuan J, et al. Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). Clin Infect Dis 2020;71 (15):799–806.

[39] Zhang B, Liu S, Tan T, et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest 2020;158(1) e9–e13.

[40] Maor Y, Cohen D, Paran N, et al. Compassionate use of convalescent plasma for treat- ment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine 2020;26:100525.

[41] Worldometer. Coronavirus update. 2020. https://www.worldometers.info/corona-virus/(accessed April 18 2020).

[42] Pecoul B. How best to prevent and treat COVID-19 in resource-limited settings? Apr 3, 2020. https://dnrlnl viewpoints/2020/how-best-prevent-treat-covid-19-resource-limited-settings-by-bernard-pecoul/.

[43] Donders V. The right to enjoy the benefits of scientific progress: in search of state obligations in relation to health. Med Health Care Philos 2011;14(4):371–81.

[44] Salazar E, Christensen PA, Graviss EA, et al. Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. Am J Pathol 2020.

[45] Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res 2020;30 (5):367–9.

[46] Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620–9.

[47] Robba C, Batragini D, Petosi P, Rocco PRM. Multiple organ dysfunction in SARS-CoV-2: mODS-CoV-2. Expert Rev Respir Med 2020;1–4.

[48] Rojas M, Rodriguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: possi- ble mechanisms of action. Autoimmun Rev 2020;102554.

[49] Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020;382(17):e38.

[50] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpa- tients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

[51] WHO. Guidance on maintaining a safe and adequate blood supply during the coronavirus disease 2019 (COVID-19) pandemic and on the collection of COVID-19 convalescent plasma. Interim guidance – 10 July 2020. 2020. https://www. who.int/publications/i/item/maintaining-a-safe-and-adequate-blood-supply- during-the-pandemic-outbreak-of-coronavirus-disease-(covid-19) (accessed July 30 2020).

[52] Zhang JS, Chen JT, Liu YX, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol 2005;77(2):147–50.

[53] Wu WT, Howell JC, Ozturk T, et al. Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection. Emerg Infect Dis 2020;26(12):2974–8 2020.

[54] Li K, Huang R, Wu M, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19. Nat Commun 2020;11 (1):6044.

[55] Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA 2020.

[56] Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan. China. J Med Virol 2020.

[57] Jynyer MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortal- ity among hospitalized patients with COVID-19: initial three-month experience. medRxiv; 2020.

[58] Libster R, Perez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Pre- vent Severe Covid-19 in Older Adults. N Engl J Med 2021;384(7):610–8.

[59] Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint with THE LANCET; 2020 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3566211.

[60] Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health 2020;25(3):210–5.

[61] US. CDC. Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings (Interim guidance). Aug 10, 2020 2020 (accessed Sep. 14 2020).

[62] WHO. Criteria for releasing COVID-19 patients from isolation. Scientific Brief. 17 June 2020 2020. https://www.who.int/publications/i/item/criteria-for-releasing- covid-19-patients-from-isolation (accessed Sep 12 2020).

[63] Li Q, Li W, Jin Y, et al. Efficacy Evaluation of Early, Low-Dose, Short-Term Cortico- steroids in Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retros-pective Cohort Study. Infect Dis Ther 2020;9(4):823–36.

[64] Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. N Engl J Med 2020.

[65] Group Recovery Collaborative, P Horby, Lim WS, et al. Dexamethasone in Hospi- talized Patients with Covid-19. N Engl J Med 2020;382(17):1623–32.

[66] Li TZ, Cao ZH, Chen Y, et al. Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. J Med Virol 2020.

[67] Ekmekci PE, Arda B. Interculturalism and Informed Consent: respecting Cul- tural Differences without Breaching Human Rights. Cultura (Iasi) 2017;14(2): 159–72.

[68] Jinaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treat- ment With Clinical Outcomes in Patients With COVID-19: a Systematic Review and Meta-analysis. JAMA 2021.

[69] Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre rando- mised controlled trial (PLACID Trial). BMJ 2020;371:m3939.

[70] Zulu JM, Sandoy IF, Moland KM, Musonda P, Munsaka E, Blystad A. The challenge of community engagement and informed consent in rural Zambia: an example from a pilot study. BMC Med Ethics 2019;20(1):45.